Interactions between cisplatin (CDDP) and irradiation are of potential significance for the combined modality treatment of cancer. Previous data have indicated that following in vitro exposure to X-irradiation certain tumour cells expressed resistance to CDDP. To identify parameters associated with this CDDP resistance, the human ovarian carcinoma cell line SK-OV-3/P was pre-exposed to fractionated X-irradiation (total dose: 50 Gy) in vitro. The resultant subline (SK-OV-3/DXR-10) proved 2-fold resistant to CDDP, but not to acute X-irradiation. Consistent with unaltered dihydrofolate reductase and thymidylate synthase activities, SK-OV-3/DXR-10 cells were neither cross-resistant to methotrexate nor to 5-fluorouracil. Verapamil (6.6 /iM) significantly (P < 0.05) enhanced CDDP-induced cytotoxkity in the resistant DXR-10 subline, but not in the parental cells. Total glutathione levels were significantly (P < 0.01) lower in the resistant subline and BSO pretreatment failed to influence cytotoxicity, whilst related enzyme activities were not consistently modified in the SK-OV-3/DXR-10 cells. Resistance in these cells was associated with significantly decreased cisplatin uptake (P < 0.002). Immediately following drug exposure the total platlnation level of the DNA, quantitated immunochemically, was higher (P < 0.05) in the resistant subline indicative of increased tolerance to DNA damage. After an 18 h post-treatment incubation the parental cell line appeared proficient in the removal of the intrastrand adduct Pt-AG, but deficient in removing the major adduct Pt-GG and the difunctional Pt-(GMP) 2 lesion, whilst the DXR-10 resistant subline appeared proficient in removal of all four Pt-DNA adducts. DNA polymerases a and /3 activities, however, were comparable in both cell lines. These data implicate both enhanced repair and increased tolerance of DNA damage as mechanisms of resistance to CDDP resulting from in vitro exposure of a human ovarian carcinoma cell line to fractionated X-irradiation.
Introduction
Clinical drug resistance has been documented in patients after treatment not only with antitumour drugs, but also with radiotherapy. Reduced response rates to chemotherapy have been reported in previously irradiated paitents with squamous cell carcinoma of the head and neck (1) and in certain patients with ovarian (2), breast (3), lung (4), uterus (5) or testicular cancer (6) . Amongst the drugs which are frequently combined with radiation, m-diamminedichloroplatinum(II) (cisplatin; CDDP*) is one of the most widely used in the treatment of a variety of solid tumours (7) . Although combined treatment widi CDDP and radiation has made a positive impact in the management of several human malignancies, many are not controlled despite this multimodality approach and optimal sequencing of each modality remains to be clarified.
In a general in vitro study of interactions between a series of clinically useful antitumour drugs and irradiation we have shown that prior exposure of human tumour cells to X-irradiation can result either in the expression of subsequent resistance or collateral sensitivity to CDDP (8) . Numerous factors have been implicated in modulating CDDP sensitivity, including modified drug accumulation (9) , altered DNA repair capacity (10, 11) , differential DNA damage tolerance (12, 13) and changes in glutathione, metallothionein and/or reduced folate metabolism (14) (15) (16) .
It is generally accepted that the antineoplastic activity of CDDP is due to its bifunctional interactions with DNA (17) , resulting in the formation of four major Pt-DNA adducts which can be detected and quantitated immuno-chemically (18) (19) (20) . Using this methodology, Hill et al. (13) have provided the first evidence that in vitro exposure to fractionated X-irradiation of an apparently repair-deficient teratoma cell line results in the expression of resistance to CDDP associated with enhanced repair and tolerance of CDDP-induced DNA damage (13) . Since these initial investigations suggested that repair of Pt-DNA adducts can be modulated by radiation, the main objective in this study was to confirm our earlier observation and to characterize the parameters associated with mis expression of CDDP resistance following exposure of tumor cells to fractionated X-irradiation.
Materials and methods

Cell lines
The SK-OV-3/P cell line, originally described as being derived from malignant ascites of a patient treated with thiopeta (21), was obtained from the American Type Culture Collection, Rockville, MD. Monolayer cultures were maintained in Eagle's medium supplemented with 10% fetal calf serum (FCS). Medium and FCS were supplied by Gibco-Biocult (Glasgow, UK).
The DXR-10 subline was derived by exposing logarithmically growing cultures of SK-OV-3/P cells to ten fractions of 5 Gy (dose reducing survival by -1 log). The total radiation dose administered (SO Gy) was within the range used in clinical radiation therapy protocols for ovarian cancers (2) . Between each X-ray fraction the medium was changed and cultures were allowed to repopulate and resume logarithmic growth. The SK-OV-3/DXR-10 subline was obtained after a period of 15 weeks in culture. Routine culture conditions of the DXR subline, once established, were identical to those used for the parental cells, which were also maintained in culture during the development of the subline. Population doubling Total GSH content and related enzyme activities were measured in cell lysates prepared from logarithmically growing cells. The assays used were: GSH content by the glutathione reductase (GR) recycling method of Griffith (23); glutathione S-transferase (GST) according to the procedure of Habig and Jackoby (24), using l-chloro-2,4-dinitrobenzene (Sigma Chemicals) as substrate; GR by the method of Horn (25); and glutathione peroxidase (GP), using cumene hydroperoxide. according to the modified method described by Paglia and Valentine (26). Cytosolic supematants used for the following assays were prepared according so the procedure of Akman et al. (27) . Catalase was then assayed by the method of Beutler (28); DT-diaphorase using the procedure of Ernster (29); and superoxide dismutase (SOD) as described by Heikkila Assays for dihydrofolate reductase (DHFR), thymidylate synthase (TS) and DNA polymerases a and 0 All enzyme assays were performed using logarithmically growing cell cultures. TS activity was measured according to the procedure of Roberts (33), with minor modifications relating to the preparation of methylene tetrahydrofolate (34). Levels of DHFR were determined spectrophotometrically as described elsewhere (35), using a Beckman Model DU spectrophotometer. Cellular protein content was estimated using the Bradford assay (32) and normalized values for both enzymes were expressed as the mean ± SE. Activities of DNA polymerases a and 0, as determined by incorporation of [ 3 HJdTTP (NEN, UK; 1.0 mCi/ml. 0.013 /tM/ml) into activated calf thymus DNA (Sigma Chemicals), were measured following the procedure described by Mivechi and Dewey (36). Activities were expressed as pmol ^HJdTTP/lO 6 cells/10 min (mean ± SE).
Cellular uptake of CDDP
Duplicate cultures of logarithmically growing SK-OV-3/P and SK-OV-3/DXR-10 cells were exposed to CDDP (10, 20 and 50 /ig/ml) for 1 h. Cells were then washed with ice-cold PBS, trypsinized and harvested. The resultant cell pellets were dried at 60°C, then dissolved in 65% HNO 3 (final volume 500 pi) (37). The amount of platinum was determined with a Perkin Elmer model 4000 atomic absorption spectrophotometer equipped with an HGA-500 graphite furnace and an AS-400 autosampling system. K 2 PtCl 6 solutions were used for calibration. The platinum detection limit is 2 pmol. DNA was then digested to nucleotides and Pt-containing oligonucleotides as described previously (19) , except that sodium azide was omitted. Separation of the digestion products was carried out using an anion exchange chromatography column (Mono-Q, Pharmacia, Sweden) (19) . Details of the enzyme-linked immunosorbent assay (ELJSA) and the polyclonal antisera used to quantitate the Pt-DNA adducts have been described in an earlier publication (38). Since Pt-DNA adducts were quantitated per /tg DNA isolated, correction for dilution by DNA synthesis during the 18 h post-treatment incubation period was carried out using parallel cell cultures, following the procedure described earlier (38). The dilution factor was calculated as the ratio of the specific activity of DNA (d.p.m. of 14 C-thymidine template-labelled DNA per 11% DNA measured spectrophotometrically) at 18 h compared with that value at 0 h. The apparent number of lesions at 18 h divided by the dilution factor gave a 'true' number of Pt-DNA adducts.
Statistical analysis
Differences were tested using the unpaired Student's f-test. P values of <0.05 were considered statistically significant.
Results
Cytotoxicity assays
Dose-response curves for the SK-OV-3/P ovarian carcinoma cell line and the subline designated SK-OV-3/DXR-10 derived by pre-exposure to fractionated X-irradiation following a 24 h or a 1 h exposure to CDDP are shown in Figure 1 . ICJO values were interpolated and a comparison (see Table II) shows that the SK-OV-3/DXR-10 subline was 2-fold more resistant (P < 0.01) 1210 at Pennsylvania State University on February 20, 2013 http://carcin.oxfordjournals.org/
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Cispiatin resistance after fractionated X-irrediation Table II . Cytotoxicity assay data on SK-OV-3/P and SK-OV-3/DXR-I0 cells "X-ray dose in Gy reducing the surviving fraction of cells to 0.37 in the exponential region of the survival curve. kExtrapolation number. c Cells were exposed to drug for 24 h and results derived from full dose-response curves are expressed in /ig/ml (mean value ± SE of triplicate assays of 2-3 separate experiments).
to the drug than the parental cell line, whereas responses to MTX and 5-FU and to acute X-irradiation were unaltered. These data therefore indicate that the X-ray fractionation protocol used resulted in a modified response to CDDP but not to the antimetabolites tested or to X-irradiation (Figure 2 ). CDDP resistance proved stable over at least 200 population doubling times in culture.
A significant increase in CDDP-induced cytotoxicity was noted for the resistant SK-OV-3/DXR-10 cells in the presence of a nontoxic concentration of VPM (2-fold, P<0.05), whereas VPM was without effect on the parental cells ( Figure 3 ). In contrast, pre-incubation of both cell lines with non-toxic concentrations of BSO (20 /xM) or CsA (5 /tg/ml) failed to influence CDDPinduced cytotoxicity (Figure 3 ).
Cellular content of GSH, GST, GR, GP, SOD, catalase and DTdiaphorase
Levels of total GSH and associated enzyme activities, normalized for cellular protein content, are listed in Table ID . The total GSH content was -50% lower (P < 0.01) in the radiation-pretreated subline. However, activities of GST and GP were significantly increased in SK-OV-3/DXR-10 cells (P < 0.001 and P < 0.01, respectively), whereas GR levels were significantly decreased (P < 0.01) compared with the parental cells. Activities of SOD and catalase were comparable in the two cell lines. DT-diaphorase levels, however, were significantly lower (P < 0.02) in the resistant subline. Assays of DHFR, TS and DNA polymerases a and /3 Activities of TS and DHFR, normalized for cellular protein content, and DNA polymerase a and /3 activities, normalized for cell number, are listed in Table IV . No significant alterations were found in any of these parameters in the DXR subline compared with the parental cells. Cellular uptake of CDDP Dose-dependence of CDDP uptake was established (data not shown) and uptake, normalized for extracellular drug concentration, proved significantly higher in the parental cells than in the resistant subline: 7.29 ± 0.40 versus 4.78 ± 0.38 pmol Pt/10 6 cells//tg CDDP (P < 0.002).
Induction and repair of Pt-DNA adducts
The specific activity of radiolabelled DNA decreased in both cell lines during the 18 h post-treatment incubation period to -80-90% of the values immediately following treatment. The calculated dilution factors were: SK-OV-3/P, 0.80 ± 0.05; SK-OV-3/DXR-10, 0.90 ± 0.04.
Upon exposure to CDDP, four types of Pt-DNA adducts are formed in cells which can be assayed after nucleolytic digestion and column chromatography as four well separated digestion products. By correction for DNA synthesis and DNA content, the total amount of adduct constituting each peak of the elution profile was calculated and these results are summarized in Figure   - 4. Total CDDP binding can be calculated by adding together the amount of the four individual adducts for each cell line. This calculation shows that immediately following treatment there is significantly more drug bound to the DNA in the resistant SK-OV-3/DXR-10 subline than to the parental cells (66.4 ±7.1 versus 45.9 ± 3.0 fmol//ig DNA; P < 0.05). In terms of the distribution of adducts, in both cell lines the major adduct was Pt-GG, comprising -60% of the total immediately after drug treatment. In the parental cell line the level of Pt-GG increased by 35 % following an 18 h post-treatment incubation period while the proportion rose to 72% of the total, suggesting that additional bifunctional platination of adjacent guanines had occurred during this time. The parental cell showed some proficiency in removal of the intrastrand adduct Pt-AG, whereas the levels of the major adduct Pt-GG and die Pt-(GMP)2 lesion were not reduced during this post-treatment incubation period. In contrast, the resistant SK-OV-3/DXR-10 cells appeared proficient in removal of all four Pt-DNA adducts quantitated during the 18 h posttreatment incubation period.
Discussion
In attempting to characterize interactions between irradiation and CDDP we exposed human ovarian carcinoma cells (SK-OV-3) to fractionated X-irradiation in vitro. The derived subline (SK-OV-3/DXR-10) expressed a significantly altered response to CDDP, but not to acute X-irradiation or to the antimetabolites. This confirms an earlier report (13) that resistance to CDDP can be expressed not only after exposure of human tumour cells to the drug itself, but also after in vitro exposure to radiation. The level of CDDP resistance (2-fold) shown under these experimental W.C.M.Derapke et al. 
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For the studies with BSO both cell lines were pre-incubated with a non-toxic concentration of BSO (20 fiM) for 24 h followed by a 1 h exposure of an ICJQ concentration of CDDP (SK-OV-3/P: 2.8 /ig/ml; SK-OV-3/DXR-10: 6.1 /ig/ml). Survival rates of cells exposed to BSO alone were 101 ± 5 and 99 ± 4% for P and DXR-10 cells, respectively. For the studies with 3-AB, cells were pre-incubated with a non-toxic concentration of 3-AB (20 mM) for 2 h followed by a 1 h exposure to an IC^ dose of CDDP. Survival rates of cells exposed to 3-AB alone were 97 ± 6 and 98 ± 3% for P and DXR-10 cells, respectively. For the studies with CsA both cell lines were preincubated with a non-toxic concentration of CsA (5 /jg/ml) for 18 h. Cells were then washed free of CsA and subsequently exposed to an ICd ose of CDDP for 1 h in fresh medium. Survival rates of cells exposed to CsA alone were 93 ± 5 and 94 ± 5% for P and DXR-10 cells, respectively. SK-OV-3/P, open boxes; SK-OV-3/DXR-10, hatched boxes.
conditions is relatively modest, but the effect is reproducibly detectable. Similar low levels of CDDP resistance have been reported in other human tumour cell lines (37, 39, 40) and are considered to be characteristic of platinum coordination complexes and possibly other alkylating agents (41 -43) . Modified GSH levels and certain GSH-related enzymes have been associated with CDDP resistance in several cell lines (12, 39, (44) (45) (46) . Intracellular inactivation of CDDP via these mechanisms, however, would not appear to be implicated in our SK-OV-3/DXR-10 subline, since GSH levels were 2-fold lower than in the parental cells and BSO pretreatment had no effect. Increased GST activities have been reported in numerous CDDPresistant cell lines (45, (47) (48) (49) (50) but not in others (51) (52) (53) . Although GST activity is increased (3.2-fold, P < 0.001) in these SK-OV-3/DXR-10 cells, since there was no associated increase in cellular thiol content, this may not account for their CDDP resistance. Furthermore the activity of DT-diaphorase, an enzyme also implicated in cellular drug detoxification (54) , was significantly decreased. In addition, Hill et al. (13) have recently shown that GST activities were unaltered in two human teratoma 1212 sublines (SuSa/DXR-10 and SuSa/DXR-13) expressing CDDP resistance following fractionated X-irradiation.
Resistance to CDDP in the SK-OV-3/DXR-10 subline was associated with significantly decreased CDDP accumulation. Surprisingly, this was associated with an increased level of drug bound to the DNA. Although reduced drug uptake has been implicated in some CDDP-resistant cell lines (9, 39, 45, 46, 55, 56) , the frequent lack of correlation between the extent of uptake and the degree of CDDP sensitivity in many other reports (9, 12, 39, 40, 44, 56, 57) suggests that there may be no simple relationship between these two parameters. Recently, Onoda et al. (58) have demonstrated the ability of certain calcium channel blockers to enhance the antitumour and antimetastatic effects of CDDP. In our study a non-toxic concentration of VPM also increased CDDP-induced cytotoxicity in the resistant SK-OV-3/DXR-10 subline but not in the parental cells. At present, however, mechanisms by which VPM enhances CDDP-induced cytotoxicity remain to be identified.
Recently published experimental studies have provided evidence that CDDP may act synergistically with antimetabolites such as MTX or 5-FU, suggesting that CDDP shares a common site of action with these drugs. Investigations have implicated the thymidylate synthase cycle, a key pathway for thymidylate and ultimately DNA synthesis (16, 59) . In support of this, other groups have reported alterations in reduced folate metabolism and associated enzyme activities in certain CDDP-resistant tumour cells which express cross-resistance to either 5-FU or MTX (16, 45, 60) . In the CDDP-resistant SK-OV-3/DXR-10 subline, however, TS and DHFR activities were unaltered and, consistent with this, these cells did not express cross-resistance to 5-FU or MTX, suggesting that resistance to CDDP in this subline may not be linked to altered reduced folate metabolism.
In terms of the specific Pt-DNA adducts formed, preferential platination occurred in the sequence pGpG in both cell lines, a finding common to other reports (20, 38, 61) . However, marked differences were noted in terms of the extent of removal of these adducts in the two cell lines following an 18 h post-treatment incubation period. In both cell lines the proportion of the bifunctional Pt-AG adducts declined with time, indicative of repair. However, levels of the major adduct Pt-GG and of the Pt-(GMP)2 lesion were not reduced in the SK-OV-3 parental cells. In contrast, substantial repair of these adducts was noted for the resistant DXR subline. These data were indicative therefore of an enhanced repair capacity being associated with the expression of CDDP resistance.
Despite resistance to CDDP, activities of the DNA polymerases a and 0 were unaltered in SK-OV-3/DXR-10 cells compared with the parental cells. Although DNA polymerase /3 is required for DNA repair synthesis (62, 63) , its precise role in short-patch and long-patch repair pathways of CDDP-induced DNA lesions is not fully understood, although Kraker and Moore (64) described elevated DNA polymerase /3 activity in their CDDP-resistant P388 subline. Conversely, we have recently reported that collateral sensitivity to CDDP in a human ovarian carcinoma cell line pre-exposed to fractionated X-irradiation in vitro was associated with decreased activity of DNA polymerase /3 (65) .
Enhanced DNA repair as a mechanism of CDDP resistance has been detected in certain CDDP-resistant cell lines (11, 13, 44, (66) (67) (68) (69) . However, these studies also provided evidence that the extent of repair did not correlate directly with the degree of CDDP resistance. These studies and the results presented here add weight to the proposal that enhanced DNA repair may contribute to drug resistance, although other mechanisms relating to enhanced tolerance of DNA damage may also be operating. The greater extent of total platination measured immediately after a 1 h exposure to CDDP and the greater number of Pt-DNA adducts formed in the SK-OV-3/DXR-10 cell line suggest that these resistant cells can tolerate increased DNA damage. This might be associated with an elevated capacity of SK-OV-3/ DXR-10 cells to bypass DNA damage and/or to decrease fidelity of the DNA polymerases involved in DNA replication and repair synthesis enabling cells to replicate on a damaged template, analogous perhaps to similar findings reported in UV-irradiated bacteria (70, 71) . Data implicating increased tolerance of CDDPinduced DNA damage as a mechanism of CDDP resistance are gradually emerging (17, 72, 73) , although the biochemical processes underlying this phenomenon are poorly understood. Bohr and Hanawalt have developed a molecular technique to study DNA repair processes in individual genes (74) (75) (76) . Using this methodology this group has demonstrated that inter-and intrastrand Pt -DNA adducts were removed more rapidly in the transcribed DHFR and c-myc genes than in the overall genome (77) . In contrast, Dong et al. (78) , using a method based on DNA denaturation/renaturation gel electrophoresis, found that CDDPinduced DNA interstrand cross-links in the c-myc gene persisted for 12-24 h. These results suggest that DNA repair can be highly variable and may be influenced by factors other than transcriptional activity. It is possible that the accumulation of DNA damage in certain genomic regions, caused by localized repair heterogeneity, may be more important than overall levels of DNA damage or repair. Since the competitive ELISA technique employed in our study measures DNA repair in the overall genome, the possibility that Pt-induced DNA adducts in SK-OV-3/DXR-10 cells might be preferentially removed in actively transcribed genes remains to be investigated.
Clsplatin resistance after fractionated X-Uradiation
The processes by which radiation 'selects' or 'induces' CDDP resistance remain to be defined. Sklar (79, 80) demonstrated that transfection of murine 3T3 cells with ras-oncogenes containing a point mutation in codon 12 or 61 can result in the expression of low but significant levels of resistance to both CDDP and radiation. Recently, Sklar and Prochownik (81) and Niimi etal. (82) found that the degree of CDDP resistance correlated directly with the level of c-myc expression while depletion of c-myc transcript levels to normal restored the original CDDP sensitivity. Interestingly, c-myc transcript levels had no effect on response to ionizing radiation suggesting a possible role for c-myc in the regulation of specific DNA repair pathways affecting DNA damage by CDDP, but not by ionizing radiation. Thus, the possibility remains that the apparently enhanced capacity of SK-OV-3/DXR-10 cells to repair Pt-DNA adducts and their ability to tolerate increased CDDP-induced DNA damage may result, at least in part, from mutation induction or increased transcript levels of certain oncogenes.
